PCBP3-AS1: A Potential Drug Target and Biomarker (G100129027)

Target Name: PCBP3-AS1

NCBI ID: G100129027

PCBP3-AS1

Other Name(s): PCBP3 antisense RNA 1

PCBP3-AS1: A Potential Drug Target and Biomarker

PCBP3-AS1, also known as patiracilin, is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and liver. It is a member of the P-cadherin family, which is a group of transmembrane proteins that play a critical role in cell-cell adhesion.

The P-cadherin family has been implicated in various diseases, including cancer, heart disease, and neurodegenerative diseases. In addition, PCBP3-AS1 has been shown to be involved in the development and progression of various diseases, including cancer.

One of the key functions of PCBP3-AS1 is its role in cell-cell adhesion. This protein helps to maintain the integrity of the cell membrane and is essential for the formation of tight junctions, which are a type of cell-cell adhesion. In addition, PCBP3-AS1 is involved in the regulation of cell signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a critical regulator of cell growth, differentiation, and inflammation. It is involved in the development and maintenance of tissues and organs, and is a potential target for drugs that are designed to treat various diseases, including cancer.

In addition to its role in cell-cell adhesion and TGF-β signaling, PCBP3-AS1 is also involved in the regulation of other signaling pathways, including the Wnt signaling pathway. This pathway is involved in the development and maintenance of tissues and organs, and is a potential target for drugs that are designed to treat various diseases, including cancer.

The identification of PCBP3-AS1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. By targeting this protein, researchers may be able to develop drugs that can inhibit its function and prevent the development and progression of diseases.

In addition to its potential as a drug target, PCBP3-AS1 may also be used as a biomarker for various diseases. This protein is expressed in a variety of tissues and is highly stable, making it a potential biomarker for a variety of diseases.

For example, PCBP3-AS1 may be used as a biomarker for the diagnosis and prognosis of various diseases, including cancer. The levels of PCBP3-AS1 have been shown to be elevated in various types of cancer, and may be used as a diagnostic marker for these diseases.

In addition, PCBP3-AS1 may also be used as a biomarker for the assessment of disease severity and response to treatment in various diseases, including cancer. The levels of PCBP3-AS1 have been shown to be elevated in various types of cancer, and may be used as a marker for the effectiveness of various treatments.

In conclusion, PCBP3-AS1 is a protein that is involved in various signaling pathways and has been implicated in the development and progression of various diseases. As a result, it is a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of PCBP3-AS1 in these diseases and to develop new treatments.

Protein Name: PCBP3 Antisense RNA 1

The "PCBP3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCBP3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets